AU738020B2 - Method for producing liposomes with increased percent of compound encapsulated - Google Patents

Method for producing liposomes with increased percent of compound encapsulated Download PDF

Info

Publication number
AU738020B2
AU738020B2 AU46579/97A AU4657997A AU738020B2 AU 738020 B2 AU738020 B2 AU 738020B2 AU 46579/97 A AU46579/97 A AU 46579/97A AU 4657997 A AU4657997 A AU 4657997A AU 738020 B2 AU738020 B2 AU 738020B2
Authority
AU
Australia
Prior art keywords
carbons
lipid
glycero
phosphocholine
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU46579/97A
Other languages
English (en)
Other versions
AU4657997A (en
Inventor
Mantripragada Bhima Sankaram
Qiang Ye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pacira Pharmaceuticals Inc
Original Assignee
Skyepharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skyepharma Inc filed Critical Skyepharma Inc
Publication of AU4657997A publication Critical patent/AU4657997A/en
Assigned to SKYEPHARMA INC. reassignment SKYEPHARMA INC. Amend patent request/document other than specification (104) Assignors: DEPOTECH CORPORATION
Application granted granted Critical
Publication of AU738020B2 publication Critical patent/AU738020B2/en
Assigned to PACIRA PHARMACEUTICALS, INC. reassignment PACIRA PHARMACEUTICALS, INC. Request to Amend Deed and Register Assignors: SKYEPHARMA INC.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AU46579/97A 1996-10-01 1997-09-29 Method for producing liposomes with increased percent of compound encapsulated Expired AU738020B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/723,583 US5997899A (en) 1996-10-01 1996-10-01 Method for producing liposomes with increased percent of compound encapsulated
US08/723583 1996-10-01
PCT/US1997/017519 WO1998014171A1 (en) 1996-10-01 1997-09-29 Method for producing liposomes with increased percent of compound encapsulated

Publications (2)

Publication Number Publication Date
AU4657997A AU4657997A (en) 1998-04-24
AU738020B2 true AU738020B2 (en) 2001-09-06

Family

ID=24906863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU46579/97A Expired AU738020B2 (en) 1996-10-01 1997-09-29 Method for producing liposomes with increased percent of compound encapsulated

Country Status (9)

Country Link
US (4) US5997899A (de)
EP (1) EP1005326B1 (de)
JP (5) JP3473959B2 (de)
AU (1) AU738020B2 (de)
CA (1) CA2267416C (de)
IL (1) IL129145A0 (de)
NO (1) NO991545L (de)
NZ (1) NZ334837A (de)
WO (1) WO1998014171A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2304096C (en) 1997-09-18 2003-09-09 Skyepharma Inc. Sustained-release liposomal anesthetic compositions
NZ504188A (en) * 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
US7157098B1 (en) * 1998-01-06 2007-01-02 Roman Perez-Soler Gene therapy of tumors using non-viral delivery system
DE69935435T2 (de) 1998-08-12 2007-12-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Mittels Ammoniumsulfatgradient hergestellte liposomale analgetische Zusammensetzungen
AU2001258106A1 (en) * 2000-05-11 2001-11-20 Celator Technologies Inc. Lipid carrier compositions for improved drug retention
WO2002090510A2 (en) * 2001-05-08 2002-11-14 Emory University Regulating immine responses using dendritic cells
WO2003015707A2 (en) * 2001-08-20 2003-02-27 Transave, Inc. Method for treating lung cancers
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
DK1463487T3 (da) * 2001-12-19 2010-08-23 Res Dev Foundation Liposomal afgivelse af vitamin-E baserede forbindelser
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
US9186322B2 (en) 2002-08-02 2015-11-17 Insmed Incorporated Platinum aggregates and process for producing the same
AU2003302314A1 (en) * 2002-08-02 2004-07-09 Transave, Inc. Platinum aggregates and process for producing the same
US20070053918A1 (en) * 2003-05-12 2007-03-08 Novosom Ag Injectable depots consisting of liposomal aggregates for the delivery of active substances
ES2426915T3 (es) 2003-09-10 2013-10-25 Brentwood Equities Ltd. Diastereoisómeros de 4-ariloxi-3-hidroxipiperidinas
HUE027483T2 (en) * 2003-12-23 2016-09-28 Novozymes Bioag As Procedures and Preparations Providing Agricultural Benefits in Legumes and Non-Legumes
US20070065522A1 (en) * 2004-03-18 2007-03-22 Transave, Inc. Administration of high potency platinum compound formulations by inhalation
JP2007529546A (ja) * 2004-03-18 2007-10-25 トランセイブ， インク． 吸入によるシスプラチンの投与
KR101462819B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
JP2008500397A (ja) * 2004-05-21 2008-01-10 トランセイブ， インク． 肺疾患及び前肺疾患状態の治療
KR100618033B1 (ko) 2004-06-21 2006-08-30 에이엔에이치 케어연구소(주) 염산독세핀을 유효성분으로 함유하는 아토피 질환 치료용외용제 조성물
MX2007004955A (es) * 2004-11-08 2007-06-14 Transave Inc Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
CA3054535A1 (en) 2005-02-18 2006-08-24 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US20070110674A1 (en) * 2005-07-29 2007-05-17 Yuhong Xu Sono-active liposomes and lipid particles and use thereof as contrast agents and active-agent delivery systems
CN1913508B (zh) * 2005-08-08 2010-05-05 华为技术有限公司 基于正交频分复用的信号调制方法及其调制装置
US20070190182A1 (en) * 2005-11-08 2007-08-16 Pilkiewicz Frank G Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
US9107824B2 (en) 2005-11-08 2015-08-18 Insmed Incorporated Methods of treating cancer with high potency lipid-based platinum compound formulations administered intraperitoneally
CA2661302A1 (en) * 2006-08-16 2008-02-21 Auspex Pharmaceuticals, Inc. Preparation and utility of opioid analgesics
WO2011062132A1 (ja) 2009-11-20 2011-05-26 コニカミノルタホールディングス株式会社 Ｗ／ｏ／ｗエマルションの製造方法およびこれを用いたリポソームの製造方法、並びにこれらの方法に用いられる孔膜
US9770414B2 (en) 2010-05-13 2017-09-26 Pacira Pharmaceuticals, Inc. Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent
ES2634669T3 (es) 2011-02-08 2017-09-28 Halozyme, Inc. Composición y formulación lipídica de una enzima de degradación de hialuronano y uso de la misma para el tratamiento de la hiperplasia benigna de próstata
RU2678433C2 (ru) 2012-05-10 2019-01-29 Пейнреформ Лтд. Депо-составы гидрофобного активного ингредиента и способы их получения
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
CA2883703C (en) 2012-09-04 2021-10-19 Eleison Pharmaceuticals, Llc Preventing pulmonary recurrence of cancer with lipid-complexed cisplatin
CA2902343C (en) 2013-03-14 2022-08-02 Becton Dickinson France S.A.S. Injectable morphine formulations
EP2968729B1 (de) 2013-03-14 2018-08-15 Fresenius Kabi Deutschland GmbH Verpackungssystem für sauerstoffempfindliche medikamenten
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
HUE043847T2 (hu) 2014-08-28 2019-09-30 Halozyme Inc Hialuronán-lebontó enzimmel és egy immun checkpoint inhibitorral végzett kombinációs terápia
EP3142656B1 (de) * 2015-01-21 2018-10-17 Pacira Pharmaceuticals, Inc. Multivesikuläre liposomformulierungen von tranexamsäure
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
CA2992789A1 (en) 2015-08-20 2017-02-23 Ipsen Biopharm Ltd. Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
JP2018528185A (ja) 2015-08-21 2018-09-27 イプセン バイオファーム リミティド リポソーム型イリノテカン及びオキサリプラチンを含む組み合わせ療法を使用して転移性膵臓癌を治療するための方法
US10456360B2 (en) 2015-10-16 2019-10-29 Ipsen Biopharm Ltd. Stabilizing camptothecin pharmaceutical compositions
MA46709A (fr) 2016-11-02 2019-09-11 Ipsen Biopharm Ltd Traitement du cancer gastrique au moyen de polythérapies comprenant de l'oxaliplatine, du 5-fluoruracile (et de la leucovorine) et de l'irinotécan sous forme liposomale
WO2019210296A1 (en) * 2018-04-27 2019-10-31 Karma Biotechnologies Multi-vesicular liposomes for targeted delivery of drugs and biologics for tissue engineering
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH588887A5 (de) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US4897308A (en) * 1975-06-30 1990-01-30 L'oreal Compositions comprising aqueous dispersions of lipid spheres
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
US4086257A (en) * 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
JPS55153713A (en) * 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
US4394372A (en) * 1980-12-22 1983-07-19 The Procter & Gamble Company Process for making lipid membrane structures
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4599227A (en) * 1983-11-07 1986-07-08 Wisconsin Alumni Research Foundation Injectable pharmaceutical preparation for the induction of multiple follicular growth
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
US5204112A (en) * 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4877619A (en) * 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
US4752425A (en) * 1986-09-18 1988-06-21 Liposome Technology, Inc. High-encapsulation liposome processing method
US4920016A (en) * 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5723147A (en) * 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
JP2666345B2 (ja) * 1987-04-16 1997-10-22 武田薬品工業株式会社 リポソーム製剤およびその製造法
US4921644A (en) * 1988-02-29 1990-05-01 Technology Unlimited, Inc. Mucin directed lipsome
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
BE1001869A3 (fr) * 1988-10-12 1990-04-03 Franz Legros Procede d'encapsulation liposomiale d'antibiotiques aminoglucosidiques, en particulier de la gentamycine.
EP0665743B1 (de) * 1992-10-14 2001-12-12 The Liposome Company, Inc. Interdigitation-fusionsliposomen und gels
WO1994026253A1 (en) * 1993-05-19 1994-11-24 The Liposome Company, Inc. Liposome having a multicomponent bilayer which contains a bioactive agent as an integral component of the bilayer
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAPMAN D LIPOSOME TECH. ED GREGORIADIS CRC PRESS, 84 VOL.1 *
KIM ET AL BIOCHIMICA BIOPHYSICA ACTA 1983 *

Also Published As

Publication number Publication date
IL129145A0 (en) 2000-02-17
US6171613B1 (en) 2001-01-09
WO1998014171A1 (en) 1998-04-09
JP2008163040A (ja) 2008-07-17
CA2267416A1 (en) 1998-04-09
US6193998B1 (en) 2001-02-27
JP2001505549A (ja) 2001-04-24
CA2267416C (en) 2007-03-27
US5997899A (en) 1999-12-07
JP2003327544A (ja) 2003-11-19
EP1005326B1 (de) 2017-05-17
US6241999B1 (en) 2001-06-05
NO991545D0 (no) 1999-03-30
JP2003327525A (ja) 2003-11-19
NO991545L (no) 1999-05-31
JP3473959B2 (ja) 2003-12-08
EP1005326A4 (de) 2006-03-22
AU4657997A (en) 1998-04-24
JP2003327526A (ja) 2003-11-19
NZ334837A (en) 2000-09-29
EP1005326A1 (de) 2000-06-07

Similar Documents

Publication Publication Date Title
AU738020B2 (en) Method for producing liposomes with increased percent of compound encapsulated
CA2303432C (en) Modulation of drug loading in multivesicular liposomes
KR100387561B1 (ko) 활성제제의조절방출을위한다중소포성리포솜의제법
JP3940177B2 (ja) 多重小胞リポソームからのｉｎ ｖｉｖｏ放出を改変するための中性脂質の利用方法
EP0280503B9 (de) Multivesikuläre Liposomen mit einer eingeschlossenen biologisch aktiven Substanz mit einem Hydrochlorid
JPH0753661B2 (ja) プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
JPH0436734B2 (de)

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: SKYEPHARMA INC.

Free format text: FORMER NAME: DEPOTECH CORPORATION

FGA Letters patent sealed or granted (standard patent)